Kedrion Biopharma an important Share Purchase Agreement with Liminal BioSciences Inc. The agreement is for the purchase of Prometic Bioproduction Inc, a production plant in Québec (the "First Closing"), and Prometic Biotherapeutics Inc, which holds the biological license application for an FDA-approved drug to treat Plasminogen Deficiency type 1 (Hypoplasminogenemia), a rare systemic disease (the "Second Closing"). Crédit Agricole Corporate and Investment Bank, Intesa Sanpaolo S.p.A., Mediobanca - Banca di Credito Finanziario S.p.A., Natixis and UniCredit Bank AG served as joint bookrunners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.11 EUR | 0.00% | +5.69% | +25.93% |
May. 09 | Stock markets cautious but positive; Nexi bullish after accounts | AN |
May. 09 | Mib bearish; focus on quarterly reports and BoE | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.93% | 12.5B | |
+16.11% | 562B | |
+13.69% | 295B | |
+18.85% | 249B | |
+24.50% | 213B | |
+24.83% | 170B | |
+20.00% | 169B | |
+8.72% | 167B | |
+5.19% | 144B | |
-15.31% | 135B |
- Stock Market
- Equities
- MB Stock
- News Mediobanca S.p.A.
- Crédit Agricole Corporate and Investment Bank, Intesa Sanpaolo S.p.A., Mediobanca - Banca di Credito Finanziario S.p.A., Natixis and UniCredit Bank AG Serve as Joint Bookrunner